C9Orf72 Hexanucleotide Repeat Expansion Pathway In Als represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
The GGGGCC hexanucleotide repeat expansion in the first intron of the C9orf72 gene is the most common genetic cause of both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), accounting for approximately 40% of familial ALS cases and 25% of familial FTD cases 1. This page describes the three principal disease mechanisms: loss-of-function, RNA foci-mediated toxicity, and dipeptide repeat protein (DPR) toxicity.
The C9orf72 gene is located on chromosome 9p21 and encodes a DENN domain protein involved in:
C9orf72 expansion causes a spectrum of disorders:
Reduced C9orf72 expression due to repeat-mediated transcriptional silencing 2:
Normal C9orf72 → Rab-GEF → Vesicle trafficking → Normal synaptic function
↓
Expanded repeat → Transcriptional silencing
↓
Reduced C9orf72 → Impaired autophagy
↓
Vesicle accumulation → Neurodegeneration
Consequences:
The expanded repeat forms toxic RNA structures that sequester RNA-binding proteins 3:
Key sequestered proteins:
Non-ATF translation of the expanded repeat produces five dipeptide repeat proteins 4:
| DPR Species | Repeat-Derived | Toxicity Mechanisms |
|---|---|---|
| Poly-GA | +1 frame | Proteasome inhibition, stress granule formation |
| Poly-GP | +1 frame | Less toxic, biomarker potential |
| Poly-GR | +2 frame | Nucleocytoplasmic transport disruption, synaptic toxicity |
| Poly-PR | +2 frame | Most toxic, liquid-liquid phase separation disruption |
| Poly-PA | +2 frame | Autophagy impairment |
DPRs, particularly poly-GR and poly-PR, disrupt nucleocytoplasmic transport 5:
C9orf72-ALS shows TDP-43 pathology in >90% of cases:
| Approach | Target | Mechanism | Status |
|---|---|---|---|
| Antisense oligonucleotides | C9orf72 mRNA | Reduce toxic RNA and DPRs | Phase 1/2 |
| CRISPR/Cas9 | Repeat expansion | Allele-specific editing | Preclinical |
| RNAi | C9orf72 transcripts | Knockdown expression | Preclinical |
| Strategy | Target | Approach | Status |
|---|---|---|---|
| Autophagy enhancers | Lysosomal function | Trehalose, rapamycin | Clinical trials |
| Nucleocytoplasmic transport | Importins | Small molecule modulators | Preclinical |
| Stress granule modulators | SG dynamics | SG disassembly promoters | Preclinical |
| Neuroinflammation | Microglia | Anti-inflammatory agents | Preclinical |
The study of C9Orf72 Hexanucleotide Repeat Expansion Pathway In Als has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.